Compare Inovio Pharmaceuticals Inc (INO) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs SYSCO Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M), while SYSCO Corporation trades at $85.47 (market cap $40.32B). The key difference: SYSCO Corporation is far larger — about 513.3× Inovio Pharmaceuticals Inc's market cap, and SYSCO Corporation pays a 2.61% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | SYY | |
|---|---|---|
Market Cap | $78.55M | $40.32B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $91.16 |
52-Week Low | $0.66 | $69.30 |
Enterprise Value | $49.56M | $53.50B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Sysco (SYY) trades at $84.73, up 1.03% today, with a bullish technical signal from moving averages and a consensus analyst price target of $88.25. The company reported strong Q4 2026 earnings, beating EPS estimates with $1.53 versus $1.51 expected, driven by U.S. foodservice volume growth and cost efficiencies. Revenue reached $81.37 billion in 2025, with net income of $1.83 billion, though profit margins remain thin at 2.08%. Recent news highlights CEO discussions on CNBC and operational initiatives, including AI-driven efficiencies.
The outlook for SYY is positive, supported by earnings beats, steady cash flow, and analyst optimism, but risks include competitive pressures, supply chain disruptions, and macroeconomic uncertainty. Upside potential exists if the company maintains volume growth and margin improvements, but investors should monitor debt levels and food safety issues highlighted in recent reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
